Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 2,293 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiac Ischemia Clear all

Conditions: ANOCA - Angina With Non-obstructive Coronary Arteries, INOCA (Ischemia With Non Obstructive Coronary Artery Disease)
Interventions: Coronary reactivity testing with and without nitrates; Diagnostic Test
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Coronary Heart Disease, Depression
Interventions: Other; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Coronary Heart Disease
Interventions: Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cardiac Disease
Interventions: GE Attenuation Corrected Hawkeye Camera; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiogenic Shock
Interventions: Heparin, Without Heparin; Drug · Other
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions: Percutaneous mitral valve repair (MitraClip Implant); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Inflammatory Lung Injury, Ischemia-Reperfusion Lung Injury, Postoperative Pulmonary Complications
Interventions: Sevoflurane, Propofol; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO)
Interventions: CTO Treatment Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: ST-segment Elevation Myocardial Infarction (STEMI)
Interventions: Cardiac magnetic resonance imaging; Diagnostic Test
Lead sponsor: Samsung Medical Center; Other
Eligibility: Not listed
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV/AIDS, Myocardial Infarction
Interventions: Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Coronary Disease, Heart Diseases, Coronary Arteriosclerosis
Interventions: Estrogens, Conjugated (USP), Medroxyprogesterone 17-Acetate, Placebo; Drug
Lead sponsor: Tufts University; Other
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Vessels, Coronary Artery Disease
Interventions: No intervention. Observational study; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atrial Fibrillation
Interventions: sphygmomanometer cuff inflations, standard of care; Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Myocardial Ischemia
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 6,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 17
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Atlanta, Georgia + 9 more

Conditions: Coronary Artery Disease
Interventions: Inclisiran sodium 300 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 27
States / cities: Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more

Conditions: Coronary Artery Disease
Interventions: regadenoson and atropine; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sarcoidosis With Myocarditis, Sarcoidosis, Healthy, ST Elevation Myocardial Infarction
Interventions: cell free DNA; Diagnostic Test
Lead sponsor: Nabeel Hamzeh; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Coronary Artery Disease, Myocardial Infarction, Coronary Disease, Coronary Stenosis, Angina Pectoris, Chest Pain
Interventions: Not listed
Lead sponsor: Angiowave Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Shock, Cardiogenic
Interventions: Tilarginine Acetate Injection intravenous infusion; Drug
Lead sponsor: Arginox Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 83
States / cities: Mobile, Alabama • Fort Smith, Arizona • Mesa, Arizona + 68 more

Conditions: Angina, Unstable, Myocardial Infarction, Ischemic Heart Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 20 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Accident
Interventions: Periodontal Treatment: SRP, Referral; Procedure
Lead sponsor: University at Buffalo; Other
Eligibility: Up to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Coronary Microcirculation, Coronary Artery Disease, Myocardial Disease, Ischemia
Interventions: Rnalozine; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing

Cardiac Markers in Depressed Patients With Coronary Heart Disease - R01HL147862

Relationship Between the Menstrual Cycle and Heart Disease in Women

Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System

HEROIC (Heparin Requirement in Counterpulsation)

Feasibility Study of a Percutaneous Mitral Valve Repair System.

Anesthetics to Prevent Lung Injury in Cardiac Surgery

EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

Angio-IMR and Cardiac MR-derived MVO in STEMI Patients

Inflammation and Cardiovascular Health in Women

Estrogen, HDL, and Coronary Heart Disease in Women

Influence of Myocardial Shortening on Coronary Tortuosity

Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

Mechanical Alternans Study

Cell Free DNA in Cardiac Sarcoidosis

Clinical Evaluation of Radiation Reduction for Optimized Safety

A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack

Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

Periodontitis and Cardiovascular Events or "PAVE"

Impact of Ranolazine on Coronary Microcirculatory Resistance